Marshall Wace, LLP Beam Therapeutics Inc. Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 55,000 shares of BEAM stock, worth $1.57 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
55,000Holding current value
$1.57 Million% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding BEAM
# of Institutions
245Shares Held
76.7MCall Options Held
458KPut Options Held
202K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$235 Million1.01% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$218 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.62MShares$218 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.07MShares$202 Million1.53% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$138 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $2.01B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...